Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291509 | 0.88 | POLB (0.42) | POLBKDM4ERAB9ANPC1 | |
| SCHEMBL3974878 | 0.77 | TSHR (0.41) | POLBKDM4EKMT2AMEN1RAB9A | |
| SCHEMBL3289956 | 0.76 | LMNA (0.50) | CYP1A2POLBPDE4BKDM4EKMT2A | |
| SCHEMBL20521059 | 0.74 | KDM4E (0.40) | CYP1A2PDE4BKDM4EKMT2AMEN1 | |
| SCHEMBL29705131 | 0.74 | KDM4E (0.40) | CYP1A2PDE4BKDM4EKMT2AMEN1 | |
| SCHEMBL1132860 | 0.72 | LMNA (0.46) | POLBADRB2KMT2AMEN1RAB9A | |
| SCHEMBL3291390 | 0.69 | LMNA (0.39) | POLBADRB2KDM4EKMT2AMEN1 | |
| SCHEMBL3296373 | 0.68 | LMNA (0.39) | ADRB2KDM4EKMT2AMEN1MAPT | |
| SCHEMBL23646765 | 0.68 | LMNA (0.44) | CYP1A2POLBPDE4BKDM4EKMT2A | |
| SCHEMBL3289057 | 0.68 | ADRB2 (0.43) | POLBADRB2KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718621-B2 | Macrolones—amino substituted quinolones | GLAXO GROUP LTD. (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| EP-1824870-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050942-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | MRPL21, Q6ZSR9, QARS1 | CYP1A2 273/4885POLB 1116/4885PDE4B 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.